Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
D Kreatsoulas, C Bolyard, BX Wu, H Cam… - Journal of Hematology & …, 2022 - Springer
Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …
Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities
M Maccari, C Baek, M Caccese, S Mandruzzato… - The …, 2024 - academic.oup.com
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor.
Standard therapies, including surgical resection, chemoradiation, and tumor treating fields …
Standard therapies, including surgical resection, chemoradiation, and tumor treating fields …
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas
GM Stergiopoulos, SC Concilio, E Galanis - Current Treatment Options in …, 2024 - Springer
Opinion statement Malignant gliomas are common central nervous system tumors that pose
a significant clinical challenge due to the lack of effective treatments. Glioblastoma (GBM), a …
a significant clinical challenge due to the lack of effective treatments. Glioblastoma (GBM), a …
Role of T cell metabolism in brain tumor development: a genetic and metabolic approach
B Yang, Z Li, P Li, B Liang, Y Liu, E Feng - BMC neurology, 2025 - Springer
Background Malignant brain tumors are among the most lethal cancers. Recent studies
emphasized the crucial involvement of the immune system, especially T cells, in driving …
emphasized the crucial involvement of the immune system, especially T cells, in driving …
Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab
C Jensen, S Maarup, HS Poulsen… - Clinical and …, 2024 - Springer
Purpose There is an unmet need for new treatment options and biomarkers for patients with
glioblastoma (GBM). Here we investigated three non-invasive biomarkers: type VI collagen …
glioblastoma (GBM). Here we investigated three non-invasive biomarkers: type VI collagen …
7aaRGD-a novel SPP1/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas
A Ellert-Miklaszewska, P Pilanc, K Poleszak, AJ Roura… - 2024 - researchsquare.com
Background Immune checkpoint inhibitors (ICIs) present clinical benefits in many cancer
patients but invariably fail in glioblastoma (GBM), the most common and deadly primary …
patients but invariably fail in glioblastoma (GBM), the most common and deadly primary …